Vitexin (Synonyms: Orientoside) |
Catalog No.GN10806
One-Click Copy Product Info
|
Vitexin is an active components of many traditional Chinese medicines, and were found in various medicinal plants.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3681-93-4
Sample solution is provided at 25 µL, 10mM.
Vitexin is an active components of many traditional Chinese medicines, and were found in various medicinal plants. Vitexin (apigenin-8-C-glucoside) has recently received increased attention due to its wide range of pharmacological effects, including but not limited to anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects [1]. vitexin has recently received increased attention due to its wide range of pharmacological effects, including anti-cancer, anti-oxidant, anti-inflammatory, anti-nociceptive, anti-AD (AD, Alzheimer's disease), anti-hypertensive, anti-spasmodic, anti-hypoxia/ischemia injury, anti-depressant-like actions and anti-viral activities [1].
Vitexin (20 µM, 24h) significantly reduced the HIF-1α level in rat pheochromocytoma PC12 cells, not in human hepatocellular carcinoma HepG2 or in human osteosarcoma HOS cells under hypoxia [2]. Vitexin reduced the levels of VEGF (the major angiogenic factor) protein and mRNA in a dose-dependent manner [2]. 20 µM of vitexin inhibited PC12 cells invasion by approximately 66% [2]. Vitexin-induced (100 µM, 48h) apoptosis was p53 dependent in human oral cancer OC2 cells [3]. Vitexin (100 µM, 48h) induced the expression of ERK 1/2 in OC2 cells [3].
Vitexin (40 mg/kg i.g.) increased the brain weights of D-galactose-aged mice [4]. vitexin (10-40 mg/kg i.g.) increased the activity of the antioxidase system and levels of ATPase in the serum and tissue of D-galactose-aged mice [4]. Vitexin (0.3-10 mg/kg, i.p.) inhibits the mice writhing response induced by acetic acid and phenyl-p-benzoquinone (PBQ) [5]. Vitexin (1-10 mg/kg, i.p.) inhibits carrageenan-, capsaicin-, and CFA-Induced mechanical and thermal hyperalgesia [5]. Vitexin (10 mg/kg, ip, 30 min before the ipl injection of carrageenan) inhibits pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, and IL-33) and enhances anti-inflammatory cytokine (IL-10) production induced by carrageenan [5].
References:
[1]. He M, Min J W, Kong W L, et al. A review on the pharmacological effects of vitexin and isovitexin[J]. Fitoterapia, 2016, 115: 74-85.
[2]. Choi H J, Eun J S, Kim B G, et al. Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic Potential in PC12 Cells[J]. Molecules & Cells (Springer Science & Business Media BV), 2006, 22(3).
[3]. Yang S H, Liao P H, Pan Y F, et al. The novel p53‐dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells[J]. Phytotherapy Research, 2013, 27(8): 1154-1161.
[4]. Dong L Y, Li S, Zhen Y L, et al. Cardioprotection of vitexin on myocardial ischemia/reperfusion injury in rat via regulating inflammatory cytokines and MAPK pathway[J]. The American Journal of Chinese Medicine, 2013, 41(06): 1251-1266.
[5]. Borghi S M, Carvalho T T, Staurengo-Ferrari L, et al. Vitexin inhibits inflammatory pain in mice by targeting TRPV1, oxidative stress, and cytokines[J]. Journal of Natural Products, 2013, 76(6): 1141-1149.
| Cell experiment [1]: | |
|
Cell lines |
Human oral cancer cell line (OC2) |
|
Preparation Method |
A total of 1000 cells were seeded in a 96-well plate for 24 h before treatment with vitexin (0, 12.5, 25, 50, 100 µM). At the end of incubation, add alamarBlue reagent in an amount equal to 10% of the volume in the well. Cultures were incubated for 4 h, and then cytotoxicty was measured by using spectrophotometry at 570 and 600 nm. |
|
Reaction Conditions |
0, 12.5, 25, 50, 100 µM for for 48 h. |
|
Applications |
Increasing concentration of vitexin drastic decreased cell viability of OC2 cells. |
| Animal experiment [2]: | |
|
Animal models |
male adult Sprague-Dawley (SD) rats |
|
Preparation Method |
rats were randomly divided into the following six groups with 16 rats in each group: (1) sham group, sham-operated without occludes the artery, (2) I/R group, I/R alone with normal saline (NS) treatment, (3) I/R + puerarin group, puerarin was administered intravenously at a dose of 30 mg/kg, beginning at coronary ischemia and again at reperfusion, (4) I/R + vitexin 6 mg/kg group, vitexin was administered intravenously at a dose of 6 mg/kg, beginning at coronary ischemia and again at reperfusion, (5) I/R + vitexin 3 mg/kg group, vitexin was administered intravenously at a dose of 3 mg/kg, beginning at coronary ischemia and again at reperfusion, (6) I/R + vitexin 1.5 mg/kg group, vitexin was administered intravenously at a dose of 1.5 mg/kg, beginning at coronary ischemia and again at reperfusion. |
|
Dosage form |
Intravenous injection, 1.5, 3, 6 mg/kg |
|
Applications |
The elevation of the ST segment was significantly enhanced in I/R group 30 min after ischemia, 30 and 60 min after reperfusion compared with sham group. Vitexin 6 mg/kg and puerarin have a significant inhibiting effect against the elevation of the ST segment 30 and 60 min after reperfusion compared with I/R group. |
|
References: [1]: Yang S H, Liao P H, Pan Y F, et al. The novel p53‐dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells[J]. Phytotherapy Research, 2013, 27(8): 1154-1161. |
|
| Cas No. | 3681-93-4 | SDF | |
| Synonyms | Orientoside | ||
| Chemical Name | 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one | ||
| Canonical SMILES | C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O | ||
| Formula | C21H20O10 | M.Wt | 432.38 |
| Solubility | DMSO：47 mg/mL (108.7 mM) | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL |
| 5 mM | 462.6 μL | 2.3128 mL | 4.6256 mL |
| 10 mM | 231.3 μL | 1.1564 mL | 2.3128 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)